A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
Epistemonikos ID: 675bc5ef4d52abfac42a37a34dacda3b7fd013a4
First added on: Dec 20, 2022